Clinical trial

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

NCT03308201

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-10-16

PhasePHASE1

Study timeline

Study start (actual)2017-10-16Date precision: day

Registry last updated2024-03-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Hemay022+exemestaneDRUG

Hemay022+letrozoleDRUG

Hemay022+ fulvestrantDRUG

Sponsors & collaborators

Tianjin Hemay Pharmaceutical Co., Ltdlead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03308201 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.